DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

Search

Ocugen Inc

Closed

0.68 6.25

Overview

Share price change

24h

Current

Min

0.62

Max

0.7

Key metrics

By Trading Economics

Income

-910K

-14M

Sales

-372K

764K

EPS

-0.05

Profit margin

-1,816.754

Employees

95

EBITDA

-603K

-13M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+926.15% upside

Market Stats

By TradingEconomics

Market Cap

57M

233M

Previous open

-5.57

Previous close

0.68

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Ocugen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 kwi 2024, 14:32 UTC

Major Market Movers

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

926.15% upside

12 Months Forecast

Average 6.67 USD  926.15%

High 8 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.6351 / 0.7995Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.